How are energy investors positioned?
Najat Khan, a Director and Chief R&D Commercial Officer at Recursion Pharmaceuticals (NASDAQ:RXRX), sold 36,599 shares of Class A Common Stock on August 18, 2025. The shares were sold at a price of $5.524, for a total value of $202,172.
According to a Form 4 filing with the Securities and Exchange Commission, Khan also disposed of 3,789 shares on August 15, 2025, to cover tax obligations. The shares were sold at a price of $5.64, for a total value of $21,369. InvestingPro analysis reveals 10+ additional insights about Recursion’s financial health and valuation, available in the comprehensive Pro Research Report.
Following these transactions, Khan directly owns 668,197 shares of Recursion Pharmaceuticals.
In other recent news, Recursion Pharmaceuticals announced its second-quarter 2025 financial results, which showed a notable revenue performance. The company reported revenue of $19.22 million, surpassing analyst expectations of $15.37 million, resulting in a 25.05% positive surprise. However, the earnings per share (EPS) did not meet projections, with the company posting an EPS of -$0.41 compared to the anticipated -$0.35, representing a 17.14% negative surprise. Despite the EPS shortfall, the revenue beat reflects positively on the company’s financial outlook. These recent developments have captured the attention of investors and analysts alike. The earnings report highlights the company’s ability to generate higher-than-expected revenue, which is a key focus for stakeholders. Analysts and investors are likely to continue monitoring Recursion Pharmaceuticals for future performance updates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.